Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119886 | 0.82 | RAB9A (0.47) | EPHX2LMNAALDH1A1GRM5RAB9A | |
| SCHEMBL1233410 | 0.81 | EPHX2 (0.40) | EPHX2LMNAALDH1A1GRM5RAB9A | |
| SCHEMBL1106840 | 0.80 | ALDH1A1 (0.43) | EPHX2LMNAALDH1A1GRM5RAB9A | |
| SCHEMBL1320486 | 0.78 | VHL (0.47) | EPHX2ALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL21690435 | 0.78 | EPHX2 (0.38) | EPHX2LMNAALDH1A1GRM5RAB9A | |
| SCHEMBL92807 | 0.78 | EPHX2 (0.42) | EPHX2LMNAALDH1A1GRM5RAB9A | |
| SCHEMBL21238768 | 0.77 | EPHX2 (0.36) | EPHX2LMNAALDH1A1GRM5RAB9A | |
| SCHEMBL19772267 | 0.77 | RAB9A (0.40) | LMNAALDH1A1RAB9AHPGDSMN1; SMN2 | |
| SCHEMBL4098437 | 0.77 | NOS3 (0.43) | RAB9AHPGDNOS3NOS1NOS2 | |
| SCHEMBL14021949 | 0.77 | RAB9A (0.36) | LMNARAB9AHPGDSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420934-B2 | PPAR agonists | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2022-08-23 | — | — | US | disclosed |
| US-11130779-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200190019-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-06-18 | — | — | US | disclosed |
| US-10550071-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-02-04 | — | — | US | disclosed |
| US-10550149-B2 | PPAR agonists and methods of use thereof | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2020-02-04 | — | — | US | disclosed |
| US-10035819-B2 | PPAR agonists and methods of use thereof | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180170857-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180170857-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-06-21 | — | — | US | disclosed |
| US-9938234-B2 | PPAR agonists | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170226154-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160023991-A1 | PPAR AGONISTS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420934-B2 | PPAR agonists | PPARG, PPARD, PPARA | EPHX2 3841/4885LMNA 1003/4885ALDH1A1 1664/4885 |
| US-20180170857-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | EPHX2 3841/4885LMNA 1003/4885ALDH1A1 1664/4885 |
| US-10550149-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | EPHX2 2831/4885LMNA 423/4885ALDH1A1 1520/4885 |
| US-20160023991-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | EPHX2 3841/4885LMNA 1003/4885ALDH1A1 1664/4885 |
| US-20200190019-A1 | PPAR AGONISTS | PPARG, PPARD, PPARA | EPHX2 3841/4885LMNA 1003/4885ALDH1A1 1664/4885 |
| US-20200216490-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | PPARD, PPARG, PPARA | EPHX2 2831/4885LMNA 423/4885ALDH1A1 1520/4885 |
| US-11130779-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | EPHX2 2831/4885LMNA 423/4885ALDH1A1 1520/4885 |
| US-10550071-B2 | PPAR agonists | PPARG, PPARD, PPARA | EPHX2 3841/4885LMNA 1003/4885ALDH1A1 1664/4885 |
| US-20170226154-A1 | PPAR AGONISTS AND METHODS OF USE THEREOF | PPARD, PPARG, PPARA | EPHX2 2886/4885LMNA 918/4885ALDH1A1 1629/4885 |
| US-10035819-B2 | PPAR agonists and methods of use thereof | PPARD, PPARG, PPARA | EPHX2 2831/4885LMNA 423/4885ALDH1A1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.